Core Insights - The article discusses the phenomenon of "middlemen profiting" in the innovative drug industry, highlighted by the strategic collaboration between BMS and BNT, which involved a $9 billion deal for the drug BNT327, originally licensed from Chinese company Pumice Biotech [1][2] - The rapid increase in valuations and the perceived undervaluation of Chinese biotech firms are emphasized, with examples illustrating how companies like Pumice and Hengrui have faced challenges in capturing the full value of their innovations [1][2][3] Summary by Sections Strategic Collaborations - BMS and BNT's partnership to develop BNT327 is valued at $9 billion, with Pumice Biotech originally licensing the drug for $55 million [1] - Hengrui Pharmaceuticals licensed its asthma drug SHR-1905 to Aiolos Bio for $25 million upfront, which was later sold to GSK for $10 billion, showcasing the significant markup in valuations [2] Market Dynamics - The article highlights the immature valuation system for innovative drug companies in China and their limited international operational capabilities, leading to unfavorable deals [2][3] - The quality of clinical data and the lack of unique assets hinder Chinese companies' bargaining power in the global market [3] Evolution of BD Transactions - The evolution of business development (BD) transactions in China is outlined, with three phases: exploration (pre-2014), development (2015-2019), and explosion (2020-present) [4][5] - The surge in BD transactions is attributed to the establishment of numerous innovative drug companies post-2010 and regulatory changes that encouraged innovation [5][6] License-in and License-out Trends - License-in transactions dominated initially, allowing companies to mitigate risks and shorten development timelines, but led to inflated prices and market bubbles [6][7] - License-out transactions have recently surpassed License-in, indicating a shift in strategy as companies seek immediate cash flow amid financial pressures [8] New Business Models - The emergence of the NewCo model allows companies to retain longer-term control over their product pipelines while attracting investment, marking a shift from traditional licensing agreements [13][14] - The NewCo model has gained traction among various biotech firms, enabling them to better manage their assets and secure funding [13][15] Future Outlook - The article concludes that while "cheap sales" of assets may continue, Chinese biotech firms are increasingly integrating into the global ecosystem, necessitating a focus on maximizing value within the international value chain [15][16]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% within the next 6-12 months [4][12]. Core Insights - The company is advancing its global leadership with the innovative dual-target antibody Ivoris, which is undergoing pivotal Phase 3 clinical trials for first-line treatment of advanced pMMR/MSS mCRC [2][3]. - The company is entering an accelerated commercialization phase, with expected sales growth from the inclusion of Ivoris and Cardunili in national health insurance by 2024 [4]. - The company has a rich pipeline with over 50 projects in development, including differentiated ADCs and various therapeutic areas such as oncology, metabolism, and autoimmune diseases [4]. Financial Projections - Revenue forecasts for 2025 and 2026 have been adjusted downwards by 15% and 16% to 3.6 billion and 5.4 billion RMB, respectively. The net profit for the same years is projected to be -96 million and 426 million RMB [4][9]. - The company anticipates revenues of 7.5 billion RMB and a net profit of 1.3 billion RMB by 2027 [4][9]. - The projected revenue growth rates are 68.65% for 2025 and 49.36% for 2026, with a significant recovery expected in net profit growth by 2027 [9][11].

Core Viewpoint - The A-share market shows positive momentum with significant gains in major indices, driven by favorable policies and strong performance in the innovative drug sector [1][3]. Policy Support - The National Medical Insurance Administration has initiated the 11th batch of centralized drug procurement, focusing on mature "old drugs" while excluding innovative drugs from this process, which is expected to provide better economic support for innovative drugs [3]. - A dual-track payment system is being established, combining basic medical insurance with commercial health insurance for innovative drugs, enhancing the financial backing for drug companies [3]. - The resumption of the fifth set of listing standards for the Sci-Tech Innovation Board and the reduction of clinical trial review periods to 30 days are creating a favorable regulatory environment for innovative drug companies [3]. Healthcare Fund Performance - The healthcare fund is operating steadily, with a total surplus of 5.31 trillion yuan, and both income and expenditure are showing year-on-year growth [4]. - Employee health insurance income increased by 3.5%, while expenditures rose by 7.6%, indicating a healthy growth trend in the sector [4]. Clinical Developments - Innovative drug companies are achieving significant milestones, such as Heng Rui Medicine's GLP-1/GIP dual-target weight loss drug showing a 19.2% average weight reduction in clinical trials, marking a breakthrough in metabolic disease treatments [4]. - Other companies are also advancing in clinical trials, with several new drug applications expected soon, reflecting the long-term value of the innovative drug industry [4]. Market Outlook - The innovative drug sector is expected to maintain high growth, driven by policy implementation, clinical data releases, and international business development [5][6]. - The introduction of a commercial health insurance directory for innovative drugs is anticipated to create a more favorable pricing environment and significantly increase the scale of payments for innovative drugs in the long term [5]. International Expansion - The trend of domestic innovative drugs moving towards global commercialization is accelerating, with expectations of over $50 billion in business development transactions in 2025 [6]. - Major academic conferences in late 2025 are expected to reveal critical data for Chinese innovative drugs, potentially enhancing their market positioning and driving new licensing deals [6]. Financial Performance - Leading companies in the innovative drug sector are transitioning from heavy R&D spending to self-sustaining business models, with profitability expected to improve due to increased commercialization of key products and enhanced R&D efficiency [7][8]. - The overall investment environment for biotech and startup pharmaceutical companies is showing signs of recovery, with a notable increase in financing events in 2025 [8]. Investment Opportunities - The innovative drug ETF Guotai (517110) is closely tracking the performance of quality innovative drug companies across A-shares and Hong Kong stocks, providing a diversified investment option [9]. - The newly issued Sci-Tech Innovation Drug ETF Guotai (589723) is expected to outperform the broader market, reflecting a stronger rebound potential in the innovative drug sector [9].

Core Insights - The report continues to recommend focusing on innovative drugs and the innovative industry chain, highlighting improvements in both domestic and overseas markets for July 2025 [5][4] - The investment strategy suggests a sustained focus on innovative drugs and related industries, with a specific portfolio of recommended stocks for A-shares and H-shares [5][6] Industry Overview - The pharmaceutical manufacturing industry reported a cumulative revenue of 994.79 billion yuan with a year-on-year decline of 1.4% from January to May 2025, while total profits decreased by 4.7% to 135.32 billion yuan [9][8] - The overall industrial added value for the pharmaceutical manufacturing sector grew by 0.9% during the same period, indicating a modest recovery [9][8] Market Performance - In June 2025, the pharmaceutical sector experienced a 0.70% increase, underperforming the CSI 300 index by 1.80% [10][11] - The medical service sector showed significant growth, with a 4.77% increase, while traditional Chinese medicine and medical commercial sectors faced declines of 1.86% and 1.23%, respectively [13][14] Investment Recommendations - The report emphasizes the potential for domestic innovative drugs to achieve sales growth supported by medical insurance negotiations and commercial health insurance [5][4] - Recommended companies with high-quality innovation capabilities include Kelun-Biotech, CanSino Biologics, and Innovent Biologics, among others [5][4] Valuation Insights - The overall valuation level of the pharmaceutical sector is currently at a PE (TTM) of 46.97, which is at the 73.1% historical percentile over the past five years [20][19] - The report indicates that the pharmaceutical sector's valuation has fully adjusted, with premium rates relative to the CSI 300 and the entire A-share market being at their five-year averages [20][19] Recent Approvals and Applications - In June 2025, four innovative drugs or biosimilars were approved for market entry, including three domestic products and one imported product [22][23] - The report tracks NDA and IND applications for innovative drugs, highlighting several key products and their respective companies [24][25][26]

港股今天虽然微跌了0.08%，主要是大金融普遍调整拖累大盘，但看上去问题也不大，因为 A 股也在上 行。 黄仁勋的言论对市场影响力相当可以，其在链博会上预言，人工智能的下个浪潮是物理AI （Physic AI）—通过算法学习物理规律预测结果，替代程序员写代码，将重塑工业与机器人领域。机器人乘势 而起，优必选（09880）公布，旗下新一代工业人形机械人Walker S2 搭载全球首创人形机械人热插拔自 主换电系统，毋须人工干预或关机即可自主换电，需时仅约3分钟，令该产品具备24小时无间断工作的 能力，可避免因充电停机导致的任务中断。这个算有了一些进步，今天涨超7%。而新入品种想象力更 强，如德昌电机控股（00179）发布公告，与上海机电订立两份股权合资协议，成立两家股权式合资企 业。第一家合资公司主要作为人形机器人解决方案的销售渠道。第二家合资公司专注于人形机器人硬件 模块及系统集成的设计和制造。每家合资公司的注册资本均为7500万元人民币（约1050万美元），看来 进军机器人行业动静挺大，今天大涨超14%。其它品种地平线机器人-W(09660)涨近5%。不光是机器 人，黄仁勋基本上所有买了H20的行业都被夸了 ...

7月17日，港股创新药全天领涨，势如破竹，高纯度+高弹性标的港股通创新药ETF（520880）场内价格 一度涨近6%，收涨5.23%，全天成交额3.74亿元，环比放量超两倍，创历史天量！ 截至今日，港股通创新药ETF（520880）已连涨7日，标的指数区间累计上涨9.4%。 | | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | | 2157 | 乐普生物-B | | 6.370 | 1.260 | 24.66% | | 2 | 2162 | 康诺亚-B | | 57.250 | 7.250 | 14.50% | | 3 | 9926 | 康方生物 | | 139.500 | 13.500 | 10.71% | | 4 | 6160 | 百济神州 | | 183.300 | 17.600 | 10.62% | | 5 | 2096 | 先声药业 | | 11.940 | 1.040 | 9.54% | | 6 | 1530 | 三生制药 | | 30.600 | 2.650 | 9.48% | | 7 ...

Market Overview - On July 17, the Hang Seng Index fell by 0.08%, closing at 24,498.95 points, with a total net inflow of HKD 1.855 billion through the southbound trading channel [1] - The total trading volume for the southbound trading was HKD 134.723 billion, with a net buy of HKD 1.855 billion [1] Southbound Trading Details - In the Shanghai Stock Exchange southbound trading, the total trading amount was HKD 85.121 billion, with a net buy of HKD 1.668 billion [1] - In the Shenzhen Stock Exchange southbound trading, the total trading amount was HKD 49.602 billion, with a net buy of HKD 0.187 billion [1] Active Stocks - The most actively traded stock in the Shanghai Stock Exchange southbound trading was Xiaomi Group-W, with a trading amount of HKD 38.09 billion, despite a closing price drop of 2.01% [1][2] - Other notable stocks included Guotai Junan International and Alibaba-W, with trading amounts of HKD 37.54 billion and HKD 34.26 billion, respectively [1] - In the Shenzhen Stock Exchange southbound trading, Xiaomi Group-W also led with a trading amount of HKD 26.80 billion [2] Net Buy/Sell Analysis - The highest net buy was for Xiaomi Group-W at HKD 6.06 billion, while the highest net sell was for Pop Mart at HKD 4.78 billion, which closed down by 0.87% [1][2] - In the Shenzhen Stock Exchange, Meituan-W had the highest net buy at HKD 3.30 billion, closing up by 1.13%, while Tencent Holdings had the highest net sell at HKD 3.79 billion, closing up by 0.10% [2]

Group 1 - The Hang Seng Index fell by 0.08% on July 17, with southbound trading totaling HKD 134.72 billion, including HKD 68.29 billion in buying and HKD 66.43 billion in selling, resulting in a net inflow of HKD 1.85 billion [1] - The southbound trading through Stock Connect (Shenzhen) had a total turnover of HKD 49.60 billion, with net buying of HKD 0.19 billion, while Stock Connect (Shanghai) had a turnover of HKD 85.12 billion, with net buying of HKD 1.67 billion [1] - The most actively traded stock by southbound funds was Xiaomi Group-W, with a total turnover of HKD 64.88 billion, followed by Alibaba-W and Guotai Junan International with turnovers of HKD 52.03 billion and HKD 50.25 billion respectively [1] Group 2 - Among the stocks with net buying, Meituan-W led with a net inflow of HKD 6.06 billion, while China Construction Bank and Xiaomi Group-W followed with net inflows of HKD 5.91 billion and HKD 3.15 billion respectively [1][2] - The stock with the highest net selling was Pop Mart, with a net outflow of HKD 8.44 billion, and Tencent Holdings and Kangfang Biotech also experienced significant net selling of HKD 3.79 billion and HKD 0.76 billion respectively [1][2] - Meituan-W has seen continuous net buying for 9 days, with a total net inflow of HKD 72.14 billion during this period [2]

Group 1 - Southbound funds recorded a total transaction of 134.72 billion HKD with a net inflow of approximately 1.86 billion HKD on July 17 [1] - Major net purchases included Meituan-W (6.06 billion HKD), China Construction Bank (5.91 billion HKD), and Xiaomi Group-W (3.15 billion HKD) [1] - Significant net sales were observed in Pop Mart (844.33 million HKD), Tencent Holdings (379.45 million HKD), and Kangfang Biotech (76.18 million HKD) [1] Group 2 - Meituan-W saw a price increase of 1.13% with net purchases of 2.76 billion HKD from the Shanghai-Hong Kong Stock Connect [1] - China Construction Bank experienced a price drop of 0.95% with net purchases of 5.91 billion HKD [1] - Xiaomi Group-W declined by 2.01% with net purchases of 6.06 billion HKD from the Shanghai-Hong Kong Stock Connect and net sales of 290.13 million HKD from the Shenzhen-Hong Kong Stock Connect [1] Group 3 - Guotai Junan International fell by 0.16% with net purchases of 1.45 billion HKD from the Shanghai-Hong Kong Stock Connect [2] - Li Auto-W increased by 9.73% with net sales of 204.21 million HKD from the Shanghai-Hong Kong Stock Connect and net purchases of 2.91 billion HKD from the Shenzhen-Hong Kong Stock Connect [2] - Pop Mart decreased by 0.87% with net sales of 47.79 million HKD from the Shanghai-Hong Kong Stock Connect and 36.64 million HKD from the Shenzhen-Hong Kong Stock Connect [2]

Core Insights - On July 17, 2025, Xiaomi Group-W (01810), Guotai Junan International (01788), and Alibaba-W (09988) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 3.809 billion, 3.754 billion, and 3.426 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Xiaomi Group-W (01810), Alibaba-W (09988), and Li Auto-W (02015) led the trading volume, with amounts of 2.680 billion, 1.777 billion, and 1.720 billion respectively [1] Southbound Stock Connect - Top Active Companies - Xiaomi Group-W (01810) had a trading amount of 3.809 billion with a net buying amount of +606 million [2] - Guotai Junan International (01788) recorded a trading amount of 3.754 billion with a net buying amount of +145 million [2] - Alibaba-W (09988) had a trading amount of 3.426 billion with a net buying amount of +30.17 million [2] - Other notable companies included Pop Mart (09992) with a trading amount of 2.162 billion and a net selling amount of -478 million, and Li Auto-W (02015) with a trading amount of 1.997 billion and a net selling amount of -204 million [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Xiaomi Group-W (01810) had a trading amount of 2.680 billion with a net selling amount of -290 million [2] - Alibaba-W (09988) recorded a trading amount of 1.777 billion with a net buying amount of +51.36 million [2] - Li Auto-W (02015) had a trading amount of 1.720 billion with a net buying amount of +29.1 million [2] - Other significant companies included Tencent Holdings (00700) with a trading amount of 1.627 billion and a net selling amount of -379 million, and Pop Mart (09992) with a trading amount of 1.316 billion and a net selling amount of -366 million [2]